Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 121-130 of 661 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

    Rochester, MN, Jacksonville, FL

  2. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Rochester, MN

  3. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

    Jacksonville, FL, Rochester, MN

  5. Minority-inclusive Imaging Biomarker-based End of Therapy Trial for 177Lu-PSMA-617

    Rochester, MN

  6. STOP-HER2: Stopping Trastuzumab in HER2+ MBC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

    Rochester, MN

  8. Pilot Study of Care at Home for Monitoring Brain Tumor Patients

    Rochester, MN

  9. Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

    Jacksonville, FL, La Crosse, WI, Rochester, MN, Eau Claire, WI

  10. Indigenous Peoples Engagement in Cancer Research Arizona

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer